Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-blind Study to Compare Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) (Xiamen Innovax Biotech Co.,Ltd.) Versus Gardasil®9 (Merck & Co., Inc.) in Healthy Females 18-26 Years of Age

NCT04782895 is registered in ClinicalTrials.gov with Xiamen University as lead sponsor.

NCT NCT04782895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04782895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-blind Study to Compare Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) (Xiamen Innovax Biotech Co.,Ltd.) Versus Gardasil®9 (Merck & Co., Inc.) in Healthy Females 18-26 Years of Age
Lead sponsor
Xiamen University
Phase
Phase 3
Overall status
Completed
Start date
March 14, 2021
Completion date
July 25, 2022
Enrollment
488 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, condylomata acuminata